Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 172

Similar articles for PubMed (Select 23817330)

1.

Clinical and immunological aspects of post-kala-azar dermal leishmaniasis in Bangladesh.

Islam S, Kenah E, Bhuiyan MA, Rahman KM, Goodhew B, Ghalib CM, Zahid MM, Ozaki M, Rahman MW, Haque R, Luby SP, Maguire JH, Martin D, Bern C.

Am J Trop Med Hyg. 2013 Aug;89(2):345-53. doi: 10.4269/ajtmh.12-0711. Epub 2013 Jul 1.

2.

Increasing incidence of post-kala-azar dermal leishmaniasis in a population-based study in Bangladesh.

Rahman KM, Islam S, Rahman MW, Kenah E, Ghalib CM, Zahid MM, Maguire J, Rahman M, Haque R, Luby SP, Bern C.

Clin Infect Dis. 2010 Jan 1;50(1):73-6. doi: 10.1086/648727. Erratum in: Clin Infect Dis. 2010 May 1;50(9):1329. Galive, Chowdhury Mohammad [corrected to Ghalib, Chowdhury Mohammad].

3.

Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.

Zijlstra EE, Khalil EA, Kager PA, El-Hassan AM.

Br J Dermatol. 2000 Jul;143(1):136-43.

PMID:
10886148
4.

Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.

Singh RP, Picado A, Alam S, Hasker E, Singh SP, Ostyn B, Chappuis F, Sundar S, Boelaert M.

Trop Med Int Health. 2012 Nov;17(11):1345-8. doi: 10.1111/j.1365-3156.2012.03067.x. Epub 2012 Aug 12.

5.

Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis.

Zijlstra EE, el-Hassan AM, Ismael A.

Am J Trop Med Hyg. 1995 Apr;52(4):299-305.

PMID:
7741164
6.

Enhanced case detection and improved diagnosis of PKDL in a Kala-azar-endemic area of Bangladesh.

Mondal D, Nasrin KN, Huda MM, Kabir M, Hossain MS, Kroeger A, Thomas T, Haque R.

PLoS Negl Trop Dis. 2010 Oct 5;4(10). pii: e832. doi: 10.1371/journal.pntd.0000832.

7.

Spectrum of skin lesions of post-kala-azar dermal leishmaniasis in kala-azar endemic areas of Bangladesh.

Sultana A, Zakaria SM, Bhuiyan SI, Habib A, Dey SK, Rahman M, Basher A.

Mymensingh Med J. 2012 Jul;21(3):529-32.

PMID:
22828555
8.

Clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar, India.

Das VN, Ranjan A, Pandey K, Singh D, Verma N, Das S, Lal CS, Sinha NK, Verma RB, Siddiqui NA, Das P.

Am J Trop Med Hyg. 2012 Jun;86(6):959-61. doi: 10.4269/ajtmh.2012.11-0467.

9.

IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.

Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D, Mallick S, Rahman M, Kar S, Goswami R, Guha SK, Pramanik N, Saha B, Ali N.

J Immunol. 2007 Oct 15;179(8):5592-603.

11.

Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).

Musa AM, Khalil EA, Mahgoub FA, Hamad S, Elkadaru AM, El Hassan AM.

Ann Trop Med Parasitol. 2005 Sep;99(6):563-9.

PMID:
16156969
12.

Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.

Das VN, Pandey K, Verma N, Lal CS, Bimal S, Topno RK, Singh D, Siddiqui NA, Verma RB, Das P.

Am J Trop Med Hyg. 2009 Mar;80(3):336-8.

13.

Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.

Thakur CP, Kumar A, Mitra G, Thakur S, Sinha PK, Das P, Bhattacharya SK, Sinha A.

Indian J Med Res. 2008 Jul;128(1):38-44.

PMID:
18820357
14.

Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.

Karki P, Koirala S, Parija SC, Sethi M, Das ML.

Southeast Asian J Trop Med Public Health. 2003 Mar;34(1):22-3.

PMID:
12971510
15.

Post-kala-azar dermal leishmaniasis in Nepal: a retrospective cohort study (2000-2010).

Uranw S, Ostyn B, Rijal A, Devkota S, Khanal B, Menten J, Boelaert M, Rijal S.

PLoS Negl Trop Dis. 2011 Dec;5(12):e1433. doi: 10.1371/journal.pntd.0001433. Epub 2011 Dec 20.

16.
17.

Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.

Das VN, Pandey K, Singh D, Forwood C, Lal CS, Das P.

J Postgrad Med. 2013 Jul-Sep;59(3):226-8. doi: 10.4103/0022-3859.118046.

18.

Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis.

Ganguly S, Das NK, Panja M, Pal S, Modak D, Rahaman M, Mallik S, Guha SK, Pramanik N, Goswami R, Barbhuiya JN, Saha B, Chatterjee M.

J Infect Dis. 2008 Jun 15;197(12):1762-71. doi: 10.1086/588387.

19.

Evaluation of serological markers to monitor the disease status of Indian post kala-azar dermal leishmaniasis.

Mukhopadhyay D, Das NK, De Sarkar S, Manna A, Ganguly DN, Barbhuiya JN, Maitra AK, Hazra A, Chatterjee M.

Trans R Soc Trop Med Hyg. 2012 Nov;106(11):668-76. doi: 10.1016/j.trstmh.2012.07.005. Epub 2012 Aug 21.

PMID:
22920931
20.

Economic consequences of post-kala-azar dermal leishmaniasis in a rural Bangladeshi community.

Ozaki M, Islam S, Rahman KM, Rahman A, Luby SP, Bern C.

Am J Trop Med Hyg. 2011 Sep;85(3):528-34. doi: 10.4269/ajtmh.2011.10-0683.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk